Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bliss Gvs Pharma Limited ( (IN:BLISSGVS) ) has shared an update.
Bliss GVS Pharma Limited’s board has approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with auditors issuing an unmodified opinion, underscoring the integrity of the company’s reported performance. The board also recommended a final dividend of 100%, or ₹1 per equity share, reflecting management’s confidence in the company’s financial strength and providing a direct payout to shareholders.
The company reappointed BDO India Services Private Limited as internal auditor for the financial year 2026-27, signaling continuity in its internal control and governance framework. The 41st Annual General Meeting is scheduled for July 15, 2026, and will be conducted via video conferencing and other audio-visual means, aligning with regulatory guidance and allowing shareholders to participate without being physically present.
More about Bliss Gvs Pharma Limited
Bliss GVS Pharma Limited operates in the pharmaceutical industry, focusing on the development and manufacture of pharmaceutical products and related healthcare offerings. The company is listed on Indian stock exchanges and serves both domestic and international markets through its range of formulations and healthcare solutions.
Average Trading Volume: 97,407
Technical Sentiment Signal: Buy
Current Market Cap: 28.49B INR
Learn more about BLISSGVS stock on TipRanks’ Stock Analysis page.